NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Immunogenicity of HPV Vaccine in Transplant Recipients.

NCT05557370

Active Not RecruitingPhase 4

Sponsor: Medical College of Wisconsin

Conditions: Chronic Kidney Diseases, Kidney Transplant

Interventions: Human Papilloma Virus vaccine (GARDASIL 9)

Countries: United States

To measure levels of HPV antibodies in post-solid-organ transplant recipients who have gotten the HPV9 vaccine.

Eligibility overview

Sex: ALL

Age: 18 Years to 45 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. Patient between the age of 18 and 45 years
2. Patient is at least 6 months post-solid-organ transplant and has not received GARDASIL 9.
3. Patient who can participate in their health care and sign informed consent.
4. Patient may have had bivalent or quadrivalent HPV vaccination previously.
5. Living or deceased donor transplant patient is eligible.

   Exclusion Criteria:
6. Contraindication: Hypersensitivity, including severe allergic reactions to yeast (a vaccine component), or after a previous dose of GARDASIL 9 or GARDASIL.
7. Patient had completed vaccination series with a nonavalent HPV vaccine (e.g., GARDASIL 9) in the past
8. Patient with a diagnosis of HIV.
9. Patient that endorses being currently pregnant.

Locations (1)

Milwaukee, Wisconsin, United States